| CAS No. | CATO-C4X-2007202 |
| Molecular Formula | C8H15IO2 |
| Molecular Weight | 270.11 g/mol |
| Category | Pharmacopoeial Impurity Standards / EP Impurities |
| Availability | In Stock |
Under current pharmacopoeial and regulatory frameworks, quality-control requirements for this class of reference material explicitly involve the control of targets including Brivaracetam Impurity 202.
CATO supplies Brivaracetam Impurity 202 (CAS CATO-C4X-2007202), a pharmacopoeial impurity reference standard (molecular formula C8H15IO2, MW 270.11 g/mol) used for the identification and quantification of trace impurities in APIs.
Owing to a carboxylic acid group, a hydroxyl group, an ether linkage, iodine substitution, Brivaracetam Impurity 202 is typically white to off-white crystalline powder. Its solid-state physicochemical attributes — including a molecular weight of 270.11 g/mol — guide the selection of appropriate sample preparation and analytical techniques. Halogen substitution (F/Cl/Br/I) produces a distinctive isotope pattern in mass spectrometry, a valuable aid for qualitative confirmation.
Recommended for quantitative analysis by HPLC, GC, LC-MS/MS, or GC-MS as an external calibration standard; it can also be used for spiked-recovery experiments, LOD/LOQ determination, and LC-MS/MS multiple-reaction-monitoring (MRM) calibration.
CATO manufactures Brivaracetam Impurity 202 under ISO 17034:2016 accreditation with dual CNAS and ANAB accreditation. Each batch is characterized by orthogonal methods and supplied with a full Certificate of Analysis (COA), ensuring metrological traceability.
| Molecular Formula | C8H15IO2 |
| Molecular Weight | 270.11 g/mol |
| Purity | 97%+ |
| Storage | Store at room temperature, keep tightly closed to prevent evaporation |
| Solubility (reference) | Soluble in methanol, acetonitrile, DMSO, water (slightly soluble) |
| Stability | Contains ester bond; hydrolyzes under strong alkaline conditions |
| Degree of Unsaturation (DBE) | 1.0 |
| Halogen Content | I-containing |